



Novel Pyrimidine Derivatives as Potential Anticancer Agents: Synthesis, Biological Evaluation and Molecular Docking Study

Beata Tylińska, Benita Wiatrak, Żaneta Czyżnikowska, Aneta Cieśla-Niechwiadowicz,
Elżbieta Gębarowska and Anna Janicka-Kłos




Figure S1. UV-Vis spectra of doxorubicin and tested compounds **4**, **5** and **7** in HEPES buffer -water (W) and 1-octanol (O) phase. Concentration of used solutions were: doxorubicin = 5×10^{-5} M and compounds 2×10^{-5} M, 1.5×10^{-5} M and 1.8×10^{-5} M respectively. Path length = 1 cm. T = 25 °C.




Figure S2. Intermolecular interactions in the active site of Topo II α (2D representation): **a)** compound 5; **b)** compound 6; **c)** compound 7.




Figure S3. ESI-MS spectrum of compound 2.




Figure S4. ${}^1\text{H}$ NMR spectrum of compound 3.




Figure S5. ¹³C NMR spectrum of compound 3.




Figure S6. ESI-MS spectrum of compound 3.




Figure S7. ¹H NMR spectrum of compound 4.




Figure S8. ¹³C NMR spectrum of compound 4.




Figure S9. ESI-MS spectrum of compound 4.




Figure S10. ¹H NMR spectrum of compound 5.




Figure S11. ¹³C NMR spectrum of compound 5.




Figure S12. ESI-MS spectrum of compound 5.




Figure S13. ¹H NMR spectrum of compound 6.




Figure S14. ^{13}C NMR spectrum of compound 6.







Figure S15. ESI-MS spectrum of compound 6.

**Figure S16.** ^1H NMR spectrum of compound 7.**Figure S17.** ^{13}C NMR spectrum of compound 7.**Figure S18.** ESI-MS spectrum of compound 7.